Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 90 Global haemophilia market is growing by mid-single digit Sales of recombinant coagulation factors RecombinateⓇ/AdvateⓇ Strategic positioning of Novo Nordisk's haemophilia portfolio NovoSevenⓇ Coagil VII® ObizurⓇ1 KogenateⓇ/Helixate® XynthaⓇ/RefactoⓇ Eloctate® NovoEight® RixubisⓇ Alprolix® Benefix® Novo Nordisk compound Status Strategic position NovoSevenⓇ Launched Maintain market leadership NovoEight® Launched Establish presence in a competitive market place Phase 33 Contribute to market conversion 30 DKK 25 billion 20 N8-GP 15 CAGR²: 4% CAGR²: 7% CAGR²: 13% 10 N9-GP 5 0 2010 2015 2010 2015 rFVIII rFIX 2010 2015 rFVIIa 1 ObizurⓇ only indicated for acquired haemophilia 2 CAGR for 5-year period changing diabetes® Filed4 Establish new treatment paradigm NovoThirteenⓇ Launched Launch first recombinant product 3 Submission of N8-GP expected 2018 pending expansion of production capacity 4 Submitted to the to the European Medicines Agency in January 2016; Submitted to the US Food and Drug Administration in May 2016 novo nordisk

View entire presentation